MEDINET Co., Ltd. AI Stock Analysis
Want to see JP:2370 full AI Analyst Report?
MEDINET Co., Ltd. (2370) AI Stock Analysis
MEDINET Co., Ltd.
(TSE/TYO:2370)
The score is held down primarily by persistent, very large losses and worsening cash burn (with declining equity despite low leverage). Technical indicators are broadly neutral with a longer-term downtrend, and valuation is difficult to support given a negative P/E and no dividend yield data.
MEDINET Co., Ltd. (2370) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.79B
- Dividend Yield
- ―
- Average Volume (3M)
- 591.41K
- Price to Earnings (P/E)
- -4.2
- Beta (1Y)
- 0.71
- Revenue Growth
- 1.41%
- EPS Growth
- 1.12%
- Country
- Japan
- Employees
- 107
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
MEDINET Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnish...
MEDINET Co., Ltd. Financial Statement Overview
Summary
Despite recent revenue growth, the financial profile is dominated by very weak profitability (large operating/net losses) and significant cash burn with sharply deteriorating free cash flow. A low-debt balance sheet reduces solvency risk, but declining equity indicates ongoing capital erosion risk if losses persist.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
15Very Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 724.63M | 810.29M | 768.50M | 661.54M | 633.67M | 683.03M |
| Gross Profit | 128.40M | 83.44M | 82.67M | 65.21M | 90.44M | 135.45M |
| EBITDA | -1.29B | -1.26B | -1.20B | -1.36B | -1.17B | -718.52M |
| Net Income | -1.41B | -1.36B | -1.28B | -1.44B | -1.25B | -843.40M |
Balance Sheet | ||||||
| Total Assets | 6.35B | 4.25B | 5.70B | 5.63B | 6.08B | 5.38B |
| Cash, Cash Equivalents and Short-Term Investments | 5.03B | 3.17B | 4.65B | 4.40B | 4.50B | 4.10B |
| Total Debt | 91.32M | 0 | 781.00K | 2.31M | 4.30M | 7.69M |
| Total Liabilities | 548.63M | 477.10M | 509.95M | 590.60M | 566.58M | 475.44M |
| Stockholders Equity | 5.80B | 3.78B | 5.19B | 5.04B | 5.51B | 4.90B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.44B | -1.25B | -1.28B | -1.14B | -633.51M |
| Operating Cash Flow | 0 | -1.41B | -1.19B | -1.26B | -1.13B | -612.08M |
| Investing Cash Flow | 0 | -565.17M | -12.71M | -2.16M | -50.35M | -18.38M |
| Financing Cash Flow | 0 | -2.55M | 1.46B | 1.16B | 1.58B | 1.08B |
MEDINET Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2370, the sentiment is Negative. The current price of 17.00 is below the 20-day moving average (MA) of 19.80, below the 50-day MA of 22.42, and below the 200-day MA of 26.48, indicating a bearish trend. The MACD of -1.60 indicates Positive momentum. The RSI at 30.18 is Neutral, neither overbought nor oversold. The STOCH value of 28.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2370.
MEDINET Co., Ltd. Peers Comparison
Overall Rating
JP:238567Neutral
JP:218350Neutral- JP:237045Neutral
JP:234244Neutral
JP:206A41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:2385 | 67Neutral | JPY 5.52B | 32.56 | ― | 4.74% | -33.44% | 3.65% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:2183 | 50Neutral | JPY 4.38B | -1.16 | ― | 4.12% | -21.55% | -497.97% |
| JP:2370 | 45Neutral | JPY 4.84B | -4.19 | ― | ― | 1.41% | 1.12% |
| JP:2342 | 44Neutral | JPY 3.42B | 105.84 | ― | ― | 8.53% | 97.93% |
| JP:206A | 41Neutral | JPY 3.96B | -4.51 | ― | ― | 84.23% | 33.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2370 | MEDINET Co., Ltd. | 17.00 | -14.00 | -45.16% | |
| JP:2183 | Linical Co., Ltd. | 194.00 | -99.92 | -34.00% | |
| JP:2342 | Trans Genic Inc. | 203.00 | 6.00 | 3.05% | |
| JP:2385 | Soiken Holdings Inc. | 211.00 | -10.57 | -4.77% | |
| JP:206A | PRISM BioLab Co. LTD | 107.00 | -94.00 | -46.77% |
MEDINET Co., Ltd. Corporate Events
MEDINET Narrows Losses on Higher Sales but Maintains No-Dividend Stance
MEDINET Co., Ltd. reported a 6.5% year-on-year increase in net sales to ¥609 million for the third quarter ended June 2026, up from ¥572 million a year earlier, but remained loss-making with an operating loss of ¥929 million and a net loss of ¥845 mi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026